Max Planck Institute for Multidisciplinary Sciences

Scinai Immunotherapeutics Innovative Plaque Psoriasis Treatment Shows Encouraging Preclinical Results

Retrieved on: 
星期三, 九月 13, 2023
China Biologic Products, IBN, Injection, Plaque, Asthma, NVS, Therapy, Dermis, AMD, University Medical Center, Hook effect, I&I, 3D, European Medicines Agency, COVID-19, Clinical trial, Infection, Inflammation, IL-17A, Psoriasis, EMA, VHH, LLY, UCB, Novartis, Patient, Lilly, Risk, Max Planck Institute for Multidisciplinary Sciences, Brussels Stock Exchange, UMG, Mab, CCL20, CXCL1, AF, Research, Moonlake, NYSE, Max Planck Society, Skin, Autoimmunity, Disease, Pharmaceutical industry, Vaccine

JERUSALEM, Sept. 13, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announces encouraging results in a preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis.

Key Points: 
  • Results from ex-vivo study in human psoriatic skin anticipated in Q4 2023; In-vivo animal study results anticipated in early 2024
    JERUSALEM, Sept. 13, 2023 (GLOBE NEWSWIRE) -- via IBN – Scinai Immunotherapeutics Ltd. (Nasdaq: SCNI) a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative inflammation and immunology (I&I) biological products primarily for the treatment of autoimmune and infectious diseases, today announces encouraging results in a preclinical study of Scinai’s anti‑interleukin 17 (IL‑17) NanoAbs as a treatment for plaque psoriasis.
  • These results suggest NanoAbs’ therapeutic potential to relieve symptoms of plaque psoriasis.
  • Research shows that targeting IL-17F isoform in addition to IL-17A provides higher efficacy in treating plaque psoriasis.
  • Scinai recently started to evaluate the anti-IL-17 NanoAbs in a full human skin model induced for plaque psoriasis to evaluate the effective dose and schedule of treatment, with in-vivo animal studies anticipated in early 2024.

BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics

Retrieved on: 
星期三, 九月 6, 2023
GMP, Inhalation, Asthma, IPO, Drug development, Failure, Half-life, University Medical Center, COVID-19, BVXV, WLA, Psoriasis, Science, HS, VHH, Hidradenitis suppurativa, CDMO, Max Planck Institute for Multidisciplinary Sciences, CGMP, Risk, UMG, CUSIP, Hook effect, Max Planck Society, IBN, Safety, Fine chemical, Vaccine, Pharmaceutical industry, Medicine

In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices.

Key Points: 
  • In the past two years, the Company has substantially revamped its senior management team and pharmaceuticals development programs and recently announced its expansion into the CDMO business under the banner Scinai Bioservices.
  • NanoAbs are alpaca-derived recombinant variable domain of heavy-chain-only antibodies and are also known as nanobodies or VHH antibodies.
  • This process can often take many years, cost hundreds of millions of dollars, yet nevertheless incurs a high rate of failure.
  • We have a sharp commercial focus and a pipeline with blockbuster potential, steeped in science, strong leadership and an expertly designed technological base.

BiondVax signs exclusive license agreement for development and commercialization of a novel anti-IL-17 antibody for treatment of autoimmune and inflammatory diseases including psoriasis

Retrieved on: 
星期一, 六月 5, 2023
National Psoriasis Foundation, Psoriatic arthritis, Disease, Human, Asthma, Therapy, Macular degeneration, IBD, University Medical Center, Hook effect, Inflammation, Max Planck Society, COVID-19, Psoriasis, Interleukin 17, BVXV, COVID, Max Planck Institute for Multidisciplinary Sciences, IL-17A, Light, VHH, Patient, Patent, Hidradenitis suppurativa, MPG, UMG, Mab, Max Planck, Knowledge, Cytokine, Transport, BiondVax, Skin, Autoimmunity, Pharmaceutical industry, Vaccine

Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.

Key Points: 
  • Psoriasis affects over 3% of U.S. population, with global biologics treatment market over $9B annually and growing with 7% CAGR.
  • Excess presence of IL‑17 is implicated in a wide range of autoimmune and inflammatory diseases including psoriasis, and therefore is the molecular target for several commercially available therapeutics.
  • Of the biological treatments, monoclonal antibodies (mAbs) targeting IL-17A were the first mAbs to be approved for treatment of plaque psoriasis.
  • BiondVax is working on plans to develop the drug also as a subcutaneous injection for systemic treatment targeting patients with moderate to severe plaque psoriasis.

Announcement of The Shaw Laureates 2023

Retrieved on: 
星期二, 五月 30, 2023
Max Planck Institute for Multidisciplinary Sciences, Interim, Shaw Prize, University, Max Planck Society, Prize, GMT, Astronomy, Mathematical sciences, Molecular biology, Cell biology, University of California, Berkeley, Structural biology, Eberly College of Science, Tsinghua University, Physics, Biophysics, Research, Health, Family, Distinguishing, Dean (education), Disease, Management, Pharmaceutical industry, Mathematics, West Virginia University, PRC, Biochemistry, Medicine

They revealed the mechanism underlying each step in gene transcription, how proper gene transcription promotes health, and how dysregulation causes disease.

Key Points: 
  • They revealed the mechanism underlying each step in gene transcription, how proper gene transcription promotes health, and how dysregulation causes disease.
  • At today's press conference in Hong Kong, The Shaw Prize Foundation announced the Shaw Laureates for 2023.
  • The Shaw Prize consists of three annual prizes: Astronomy, Life Science and Medicine, and Mathematical Sciences, each bearing a monetary award of US$1.2 million.
  • This will be the twentieth year that the Prize has been awarded and the presentation ceremony is scheduled for Sunday, 12 November 2023 in Hong Kong.

Announcement of The Shaw Laureates 2023

Retrieved on: 
星期二, 五月 30, 2023
Max Planck Institute for Multidisciplinary Sciences, Interim, Shaw Prize, University, Max Planck Society, Prize, GMT, Multimedia, Astronomy, Mathematical sciences, Molecular biology, Cell biology, University of California, Berkeley, Structural biology, Eberly College of Science, Tsinghua University, Physics, Biophysics, Research, Health, Family, Distinguishing, Dean (education), Disease, Management, Pharmaceutical industry, Mathematics, West Virginia University, PRC, Biochemistry, Medicine

They revealed the mechanism underlying each step in gene transcription, how proper gene transcription promotes health, and how dysregulation causes disease.

Key Points: 
  • They revealed the mechanism underlying each step in gene transcription, how proper gene transcription promotes health, and how dysregulation causes disease.
  • At today's press conference in Hong Kong, The Shaw Prize Foundation announced the Shaw Laureates for 2023.
  • The Shaw Prize consists of three annual prizes: Astronomy, Life Science and Medicine, and Mathematical Sciences, each bearing a monetary award of US$1.2 million.
  • This will be the twentieth year that the Prize has been awarded and the presentation ceremony is scheduled for Sunday, 12 November 2023 in Hong Kong.

BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update

Retrieved on: 
星期一, 四月 17, 2023
Exercise, SAB, Human, Drug development, Table, University Medical Center, Hook effect, Max Planck Society, COVID-19, CGMP, BVXV, GAAP, Associate, Psoriasis, VHH, CDMO, Patient, Organic compound, Annual report, Risk, Laboratory, Max Planck Institute for Multidisciplinary Sciences, MPG, IL-17, UMG, Immune system, Growth, Security (finance), Cytokine, EIB, BiondVax, Caregiver, Global Research Collaboration for Infectious Disease Preparedness, Cryptocurrency, Vaccine, Fine chemical, Pharmaceutical industry, VOC

At the same time, the Company filed its Annual Report on Form 10-K with the Securities and Exchange Commission.

Key Points: 
  • At the same time, the Company filed its Annual Report on Form 10-K with the Securities and Exchange Commission.
  • In addition, having access to a multi-asset pipeline would hedge BiondVax’s risk and provide greater opportunity and flexibility in pursuing partnering deals with other pharma companies.
  • As of December 31, 2022, BiondVax had cash and cash equivalents of $14 million as compared to $17.3 million as of December 31, 2021.
  • The complete audited financial results are available in the Company’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission.